Iambic Therapeutics' Cancer Trial Data, Partnerships Validate AI Platform, BofA Says

MT Newswires Live11-10

Iambic Therapeutics' (IAM) clinical data from the IAM1363 cancer trial and multiple high-value partnerships validate its artificial intelligence platform, BofA Securities said in a Monday note.

Analysts said Iambic's more than $2 billion in investments from Takeda (TAK), AbbVie (ABBV), Bayer, and RevMed shows that the industry values the platform.

Iambic trades below competitors like Recursion Pharmaceuticals (RXRX) and Schrodinger (SDGR), and faces upside potential, BofA said.

"AI may eventually lower development costs, but today Iambic must fund both its technology and a growing pipeline," analysts said.

BofA initiated coverage on the stock with a buy rating and a $30 price target.

Shares of the company were up 30% in Monday trading.

Price: 13.11, Change: +2.94, Percent Change: +28.86

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2682710387?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-11-10 00:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2682710387","market":"fut","top_or_hot":-1,"title":"Iambic Therapeutics' Cancer Trial Data, Partnerships Validate AI Platform, BofA Says","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/IAM\">Iambic Therapeutics</a>' (IAM) clinical data from the IAM1363 cancer trial and multiple high-value partnerships validate its artificial intelligence platform, BofA Securities said in a Monday note.</p><p>Analysts said Iambic's more than $2 billion in investments from Takeda (TAK), AbbVie (ABBV), Bayer, and RevMed shows that the industry values the platform.</p><p>Iambic trades below competitors like <a href=\"https://laohu8.com/S/RXRX\">Recursion</a> Pharmaceuticals (RXRX) and Schrodinger (SDGR), and faces upside potential, BofA said.</p><p>\"AI may eventually lower development costs, but today Iambic must fund both its technology and a growing pipeline,\" analysts said.</p><p>BofA initiated coverage on the stock with a buy rating and a $30 price target.</p><p>Shares of the company were up 30% in Monday trading.</p><p>Price: 13.11, Change: +2.94, Percent Change: +28.86</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Iambic Therapeutics' Cancer Trial Data, Partnerships Validate AI Platform, BofA Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIambic Therapeutics' Cancer Trial Data, Partnerships Validate AI Platform, BofA Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-11-10 00:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/IAM\">Iambic Therapeutics</a>' (IAM) clinical data from the IAM1363 cancer trial and multiple high-value partnerships validate its artificial intelligence platform, BofA Securities said in a Monday note.</p><p>Analysts said Iambic's more than $2 billion in investments from Takeda (TAK), AbbVie (ABBV), Bayer, and RevMed shows that the industry values the platform.</p><p>Iambic trades below competitors like <a href=\"https://laohu8.com/S/RXRX\">Recursion</a> Pharmaceuticals (RXRX) and Schrodinger (SDGR), and faces upside potential, BofA said.</p><p>\"AI may eventually lower development costs, but today Iambic must fund both its technology and a growing pipeline,\" analysts said.</p><p>BofA initiated coverage on the stock with a buy rating and a $30 price target.</p><p>Shares of the company were up 30% in Monday trading.</p><p>Price: 13.11, Change: +2.94, Percent Change: +28.86</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AIPO","symbol_name":"Defiance AI and Power Infrastructure ETF","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2682710387","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2682710387","pubTimestamp":1794242247,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Iambic Therapeutics'  clinical data from the IAM1363 cancer trial and multiple high-value partnerships validate its artificial intelligence platform, BofA Securities said in a Monday note.Analysts said Iambic's more than $2 billion in investments from Takeda , AbbVie , Bayer, and RevMed shows that the industry values the platform.Iambic trades below competitors like Recursion Pharmaceuticals  and Schrodinger , and faces upside potential, BofA said.\"AI may eventually lower development costs, but today Iambic must fund both its technology and a growing pipeline,\" analysts said.BofA initiated coverage on the stock with a buy rating and a $30 price target.Shares of the company were up 30% in Monday trading.Price: 13.11, Change: +2.94, Percent Change: +28.86","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AIPO":"Defiance AI and Power Infrastructure ETF","FTXH":"First Trust Nasdaq Pharmaceuticals ETF","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC","BK4609":"英伟达持仓股","RXRX":"Recursion Pharmaceuticals, Inc.","LU0058720904.USD":"联博国际健康护理基金A","TAK":"武田制药","LU0211327993.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (USD) ACC","IE00BVYPNW00.USD":"GUINNESS GLOBAL EQUITY INCOME \"C\" (USD) ACC","ARTY":"ISHARES FUTURE AI & TECH ETF","VHT":"Vanguard Health Care ETF","BK7091":"特殊金融服务","LU1732800096.USD":"摩根大通环球收益基金A (irc)","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","ABBV":"艾伯维公司","IAM.AU":"Income Asset Management Group Ltd","IXJ":"全球医疗业ETF-iShares","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","LU2237443465.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) INC","GLAM":"Corgi Beauty, Skincare & Aesthetics ETF","BK4548":"巴美列捷福持仓","LU2129689514.USD":"FRANKLIN GLOBAL INCOME \"A\" (USD) INC","FHLC":"Fidelity MSCI Health Care Index","PPH":"VanEck Pharmaceutical ETF","VTHR":"Vanguard Russell 3000 ETF","LU1934455277.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"AD\" (USD) INC","MEDX":"HORIZON KINETICS MEDICAL ETF","XLV":"健康照护类股ETF-SPDR","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","AGNG":"Global X Aging Population ETF","RXL":"ProShares Ultra Health Care","PJP":"INVESCO PHARMACEUTICALS ETF","LU0310799852.SGD":"FTIF - Templeton Global Equity Income A MDIS SGD","LU1839511570.USD":"WELLS FARGO GLOBAL FACTOR ENHANCED EQUITY \"I\" (USD) ACC","CHAT":"ROUNDHILL GENERATIVE AI & TECHNOLOGY ETF","IYH":"iShares U.S. Healthcare ETF","TRUH":"VanEck Healthcare TruSector ETF","BK4581":"高盛持仓","LU0738911758.USD":"Blackrock Global Equity Income A6 USD","AGIX":"通用人工智能 ETF-AGIX","LU0545039389.USD":"BGF GLOBAL EQUITY INCOME \"A2\" ACC","JDOC":"JPMORGAN HEALTHCARE LEADERS ETF","BK4534":"瑞士信贷持仓","IAM":"Iambic Therapeutics","LU0868494708.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) INC","QTOC":"Innovator Growth Accelerated Plus ETF - October","SDGR":"Schrodinger Inc.","LU1929549753.HKD":"FRANKLIN INCOME \"A\" (HKD) INC","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC"},"translate_title":"美国银行表示，Iambic Therapeutics 的癌症试验数据和合作伙伴关系验证了人工智能平台","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FHLC":0.6,"IAM":1.5,"IAM.AU":1,"RXL":0.6,"GLAM":0.6,"TRUH":0.6,"AIPO":1.5,"IYH":0.6,"ARTY":1.5,"ABBV":1,"PPH":0.6,"PJP":0.6,"CHAT":1.5,"FTXH":0.6,"XLV":0.6,"QTOC":1.5,"TAK":1,"IXJ":0.6,"SDGR":1,"VHT":0.6,"MEDX":0.6,"RXRX":1,"VTHR":1.5,"JDOC":0.6,"AGNG":0.6,"AGIX":1.5},"content_text":"Iambic Therapeutics' (IAM) clinical data from the IAM1363 cancer trial and multiple high-value partnerships validate its artificial intelligence platform, BofA Securities said in a Monday note.Analysts said Iambic's more than $2 billion in investments from Takeda (TAK), AbbVie (ABBV), Bayer, and RevMed shows that the industry values the platform.Iambic trades below competitors like Recursion Pharmaceuticals (RXRX) and Schrodinger (SDGR), and faces upside potential, BofA said.\"AI may eventually lower development costs, but today Iambic must fund both its technology and a growing pipeline,\" analysts said.BofA initiated coverage on the stock with a buy rating and a $30 price target.Shares of the company were up 30% in Monday trading.Price: 13.11, Change: +2.94, Percent Change: +28.86","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2682710387","isCrawlerRequest":true}